In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.


Cedazuridine is used in a combination product with decitabine. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. It might be possible to breastfeed safely during intermittent cedazuridine-decitabine therapy with an appropriate period of breastfeeding abstinence. The manufacturer recommends an abstinence period of 2 weeks after the last dose of the cedazuridine-decitabine combination. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[1] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[2]

Publication types

  • Review